GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and ...

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies, today issued a statement in response to the World Health Organization’s ...

Shares of GeoVax Labs Inc. ($GOVX), SIGA Technologies Inc. ($SIGA), and Emergent Biosolutions Inc. ($EBS) gained in mid-day trading on Friday after the World Health ...

Data from Two Key Studies Highlight CrossReactivity and BroadSpectrum Immunity of GEO-CM04S1 and GeoVax Multi-Antigen Vaccine ...

GeoVax Labs Inc.’s stock soared 43% Monday to lead a fresh rally among companies developing treatments for mpox, after rival Siga Technologies Inc. said a trial of its antiviral failed to meet i ...

The $20 million will be used to accelerate three ongoing clinical trials by the company for Covid-19 vaccines and cancer treatments. In January, GeoVax raised $10 million for the same clinical trials.

ATLANTA, GA - June 10, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies against infectious ...

10,000-participant randomized Phase 2b study will evaluate and compare GeoVax's multi-antigen, vaccine candidate (GEO-CM04S1) to an approved vaccine against COVID-19 under BARDA's Clinical Studies ...

ATLANTA, GA and BERLIN, Germany, Sept. 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing vaccines and immunotherapies against ...

Access GeoVax Labs stock price history with daily data, historical prices, all-time highs, and stock chart history. Download and analyze trends easily.